NCT00894413已完成2 期
A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2007年5月8日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 45
- 试验地点
- 1
- 主要终点
- Change in Immune Response After Tadalafil Administration
研究概览
简要总结
The purpose of this trial is to determine whether or not Cialis (tadalafil) administered to head and neck squamous cell cancer patients augments immune response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed, previously untreated invasive head and neck squamous cell carcinoma OR histologically confirmed not yet treated recurrent head and neck squamous cell carcinoma (must be at least 3 months after diagnosis and completion of treatment for primary disease or last recurrence).
- •Disease location amenable to biopsy in outpatient clinical setting or operative biopsy within routine accepted schedule and practice of clinical care
- •No medical contraindication to biopsy of target lesion.
- •ECOG performance status 0-1
- •Required laboratory data (to be obtained within 4 weeks of initiation):
- •Platelets > 75,000/mm³
- •Calculated Creatinine Clearance (CRCL)> 60 mL/min iii. Total serum bilirubin < 1.5 mg/dL.
- •No intercurrent illness likely to prevent protocol therapy or surgical resection
- •Patients with a history of a curatively treated malignancy must be disease-free and have a survival prognosis that exceeds five years.
- •Female patients must not be pregnant or breast feeding. A negative pregnancy test is required within 14 days of randomization for all women of childbearing potential.
- •Willingness and ability to give signed written informed consent.
排除标准
- •Known severe hypersensitivity to tadalafil or any of the excipients of this product
- •Patients who have a concurrent malignancy or a history of previous malignancy treated with curative therapy within the last 3 months (other than squamous/basal cell cancer of the skin or cervical cancer) who have a survival prognosis of < 5 years.
- •Treatment with a non-approved or investigational drug within 30 days before day 1 of trial treatment.
- •Incomplete healing from previous oncologic or other major surgery.
- •Pregnancy or breast feeding (women of childbearing potential).
- •As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease).
- •Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the trial.
- •Current therapy with ketoconazole or oral antifungal therapy.
- •History of significant hypotensive episode requiring hospitalization.
- •A history of acute myocardial infarction within prior 3 months, uncontrolled angina,
- •Uncontrolled arrhythmia, or uncontrolled congestive heart failure
- •History of any of the following cardiac conditions:
- •Angina requiring treatment with long-acting nitrates.
- •Angina requiring treatment with short-acting nitrates within 90 days of planned tadalafil administration.
- •Unstable angina within 90 days of visit 1 (Braunwald 1989).
- •Positive cardiac stress test without documented evidence of subsequent, effective cardiac intervention.
- •History of any of the following coronary conditions within 90 days of planned tadalafil administration:
- •Myocardial Infarction.
- •Coronary artery bypass graft surgery.
- •Percutaneous coronary intervention (for example, angioplasty or stent placement).
- •Any evidence of heart disease (NYHA≥Class III as defined in Protocol Attachment LVHG.3) within 6 months of planned tadalafil administration
- •Current treatment with nitrates.
- •Current systemic treatment with a potent cytochrome P450 3A4 (CYP3A4) inhibitor such as ketoconazole or ritonavir.
- •Received treatment within the last 30 days with a drug or device that has not received regulatory approval for any indication at the time of Visit
- •Prior chronic immune suppressive state (AIDS, immunosuppressive therapy).
- •History of hypotension and/or blindness during prior treatment with Tadalafil or other PDE-5 inhibitors.
- •prior history of non-arterial ischemic optic retinopathy
研究组 & 干预措施
Placebo
Placebo Comparator
干预措施: Placebo Pill (Other)
Tadalafil
Experimental
Tadalafil 20 mg once per day
干预措施: Tadalafil (Drug)
结局指标
主要结局
Change in Immune Response After Tadalafil Administration
时间窗: Change from baseline to up to 14 days post-intervention
Median fold-change in immune response of T-cell expansion, delayed-type hypersensitivity reactions, CD4/CD69, CD8/CD69. A positive value indicates an increase in immune response.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study of Tadalafil for the Treatment of Diabetic Patients With Symptoms of Upset Stomach and Delayed Stomach EmptyingGastroparesisNCT00050609Eli Lilly and Company2
已完成
3 期
Effect of Tadalafil Once a Day in Men With Erectile DysfunctionErectile DysfunctionNCT00836693Eli Lilly and Company217
已完成
3 期
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)Benign Prostate HyperplasiaErectile DysfunctionNCT01937871Eli Lilly and Company909
已完成
2 期
Tadalafil in Subjects With Mild to Moderate HypertensionHypertensionNCT00157326Eli Lilly and Company180
进行中（未招募）
2 期
Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ CancerGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaNCT05709574University of Arizona11